ストックスクリーナーアプリを入手
560.00
1.44%
-8.20
アフターアワーズ：
561.51
1.51
+0.27%
前日終値:
$568.20
開ける：
$567.34
24時間の取引高:
602.53K
Relative Volume:
0.61
時価総額：
$58.34B
収益：
$14.21B
当期純損益:
$4.46B
株価収益率:
14.11
EPS:
39.68
ネットキャッシュフロー:
$3.56B
1週間 パフォーマンス:
-2.33%
1か月 パフォーマンス:
+0.62%
6か月 パフォーマンス:
-18.78%
1年 パフォーマンス:
-51.91%
1日の値動き範囲:
$559.45
$570.00
1週間の範囲:
$552.81
$571.20
52週間の値動き範囲:
$476.49
$1,170.58
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
名前
Regeneron Pharmaceuticals Inc
セクター
電話
(914) 847-7000
住所
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
REGN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-14 | 開始されました | Rothschild & Co Redburn | Buy |
| 2025-06-30 | ダウングレード | Argus | Buy → Hold |
| 2025-05-30 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | アップグレード | Citigroup | Neutral → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-02-05 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | ダウングレード | UBS | Buy → Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-09-24 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | 開始されました | Bernstein | Outperform |
| 2024-01-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-03 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | 繰り返されました | Oppenheimer | Perform |
| 2023-06-28 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | アップグレード | Jefferies | Hold → Buy |
| 2023-03-23 | アップグレード | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | アップグレード | Cowen | Market Perform → Outperform |
| 2023-01-20 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-10-26 | ダウングレード | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-09-09 | アップグレード | Jefferies | Underperform → Hold |
| 2022-09-09 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-06 | 開始されました | Jefferies | Underperform |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2022-01-05 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2022-01-03 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | 再開されました | Wells Fargo | Overweight |
| 2021-12-07 | 再開されました | Cowen | Market Perform |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 再開されました | BMO Capital Markets | Outperform |
| 2021-11-05 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2021-06-29 | 開始されました | H.C. Wainwright | Buy |
| 2021-01-25 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | アップグレード | The Benchmark Company | Hold → Buy |
| 2021-01-08 | アップグレード | Citigroup | Neutral → Buy |
| 2020-10-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | ダウングレード | The Benchmark Company | Buy → Hold |
| 2020-07-09 | アップグレード | SunTrust | Hold → Buy |
| 2020-05-26 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-04-17 | アップグレード | The Benchmark Company | Hold → Buy |
| 2020-04-08 | 開始されました | The Benchmark Company | Hold |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-02-27 | 開始されました | Barclays | Overweight |
| 2020-02-26 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | アップグレード | Jefferies | Hold → Buy |
| 2020-02-11 | アップグレード | Argus | Hold → Buy |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-16 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-12-13 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | 開始されました | SunTrust | Hold |
| 2019-11-07 | アップグレード | Citigroup | Neutral → Buy |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-09-23 | アップグレード | Guggenheim | Neutral → Buy |
すべてを表示
Regeneron Pharmaceuticals Inc (REGN) 最新ニュース
Does Regeneron Offer Value After Shares Slide 21.7% Year to Date in 2025? - simplywall.st
Fortis Capital Advisors LLC Reduces Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Plato Investment Management Ltd Increases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Scientech Research LLC Lowers Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s CEO On His Ten ‘Ignored’ Pipeline Blockbusters - insights.citeline.com
Acadian Asset Management LLC Acquires 56,816 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sandoz reaches agreement with Regeneron, resolving all patent litigation related to its US aflibercept biosimilar - Eyes On Eyecare
Ilmarinen Mutual Pension Insurance Co Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Ascent Group LLC Raises Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Voleon Capital Management LP Increases Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sepio Capital LP Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Teza Capital Management LLC - MarketBeat
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Tamar Securities LLC - MarketBeat
Phase III success for Regeneron signals pozelimab and cemdisiran’s entry into MG market - Yahoo Finance
Woodline Partners LP Has $67.37 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Banque Transatlantique SA Reduces Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
UniSuper Management Pty Ltd Acquires 496 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Nissay Asset Management Corp Japan ADV Purchases 2,292 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Focus Partners Advisor Solutions LLC Invests $538,000 in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
DnB Asset Management AS Purchases 14,323 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
MAI Capital Management Has $566,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
United Services Automobile Association Buys Shares of 2,477 Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sandoz, Regeneron Settle Eye Drug Patent Claims - Law360
Regeneron’s fast-acting IgG promises alternative to frequent allergy shots - biocentury.com
Gotham Asset Management LLC Purchases 20,624 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
REGENERON ALERT: Bragar Eagel & Squire, P.C. is - GlobeNewswire
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
Regeneron's Libtayo Combo Achieves Nearly Double Survival Rate In Advanced Lung Cancer Compared To Chemotherapy - AOL.com
Alliancebernstein L.P. Decreases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
AQR Capital Management LLC Purchases 28,865 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Can You Keep The Cat and The Relationship? Regeneron Thinks So - insights.citeline.com
A Look at Regeneron (REGN) Valuation After Positive Phase 3 Results in Myasthenia Gravis Trial - simplywall.st
Regeneron Deal Lets Sandoz Launch Eylea Biosimilar in Late 2026 - Bloomberg Law News
Regeneron’s cat and birch allergy mAbs score in Phase III trials - Yahoo Finance
Sandoz and Regeneron reach agreement over biosimilar dispute - Ophthalmology Times
Regeneron settles patent dispute with Sandoz over Eylea biosimilar - Seeking Alpha
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’ - BioSpace
Libtayo plus chemotherapy results at five years reinforce significant and durable improvements in survival - MarketScreener
Sandoz Eyes 2026 Aflibercept Launch With Regeneron Eylea Settlement - insights.citeline.com
Sandoz and Regeneron settle aflibercept dispute, paving way for US debut - The Pharma Letter
Five-Year Data from Regeneron's EMPOWER-Lung 3 Trial Shows Libtayo Plus Chemotherapy Significantly Improves Overall Survival in Advanced NSCLC Patients - Quiver Quantitative
19.4% vs 8.8%: Regeneron's Libtayo Doubles Long-term Survival in Advanced Lung Cancer Trial at 5 Years - Stock Titan
Vident Advisory LLC Cuts Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Says Experimental Therapy Reduced Symptoms Of Cat, Birch Allergies In Late-Stage Trials - Stocktwits
Flputnam Investment Management Co. Sells 5,992 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded at Raymond James Financial - MarketBeat
Royal Bank of Canada Trims Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
What's Happening With Regeneron Pharmaceuticals Stock On Monday? - Benzinga
Regeneron's allergen-blocking antibodies score phase 3 wins against cat, pollen allergies - Fierce Biotech
Regeneron Pharmaceuticals Inc (REGN) 財務データ
収益
当期純利益
現金流量
EPS
0.57%
0.10%
大文字化:
|
ボリューム (24 時間):